MaxCyte, Inc.
Financials
Valuation Metrics
MaxCyte, Inc.'s Market Cap is $149M. At end of 2025 it was $165M. Ranked #3011 of 3,118 in US market (top 97%), #1384 of 1,474 on NASDAQ (top 94%), #192 of 203 in Health Care Equipment & Services (top 95%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $149M | US#3,011/3,118 Sec#192/203 |
| Revenue | $31M | US#2,771/3,118 Sec#197/203 |
| Net Income | $-36M | US—/3,118 Sec—/203 |
| Total Assets | $185M | US#2,994/3,118 Sec#188/203 |
| Net Assets | $159M | US#2,724/3,118 Sec#166/203 |
| Employees | 91 | US#2,632/3,118 Sec#182/203 |
| Value | ||
| P/B | 0.94x | US#427/3,118 Sec#17/203 |
| P/S | 4.79x | US#2,336/3,118 Sec#152/203 |
| FCF Yield | -16.01% | US—/3,118 Sec—/203 |
| Profitability | ||
| ROE | -22.45% | US#2,499/3,118 Sec#153/203 |
| ROA | -19.30% | US#2,779/3,118 Sec#177/203 |
| Op. Margin | -111.63% | US#2,715/3,118 Sec#195/203 |
| Revenue Growth | -13.15% | US#2,587/3,118 Sec#194/203 |
| Financial Health | ||
| Debt Ratio | 16.33% | US#187/3,118 Sec#18/203 |
| Total Debt | $17M | US#2,759/3,118 Sec#178/203 |
| FCF | $-24M | US#2,431/3,118 Sec#161/203 |
| Cash | $15M | US#2,902/3,118 Sec#193/203 |
| Current Ratio | 12.26x | US#197/3,118 Sec#5/203 |
| Performance | ||
| 1Y Return | -6.49% | US#1,673/3,118 Sec#124/203 |
| 1M Return | 34.58% | US#30/3,118 Sec#7/203 |
| From 52W High | -22.99% | US#1,197/3,118 Sec#99/203 |
| 1Y MDD | -62.90% | US#2,794/3,118 Sec#176/203 |
| Trading | ||
| Volume | 1,221,421 shares | US#1,569/3,118 Sec#100/203 |
| Trading Value | $2M | US#2,938/3,118 Sec#186/203 |
| Per Share | ||
| EPS | $-0.35 | US—/3,118 Sec—/203 |
| BPS | $1.54 | US#2,625/3,118 Sec#172/203 |
Company Info
MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.